CURRICULUM VITAE. Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer.
|
|
- Leonard Woods
- 8 years ago
- Views:
Transcription
1 CURRICULUM VITAE Personal Details Surname: KARAOGLU First Name: Aziz Akademic title/ position: Asscociate Proffessor Key Qualifications: -Internal Medicine, -Medical Oncology Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer. International Experience/Collaborations: - Contact Details: Work Address: Firat University, Medical School, Medical Oncology Department Name of Hospital: Firat University Hospital Street:... Town: ElAZIG Country: Turkey Post Code:... Phone/Fax: / azizk6@yahoo.com Date of Birth: Place and Country of Birth: IZMIR, TURKEY Country of Citizenship: Republic of Türkiye Country of Training: Türkiye First Language: Turkish Languages: English
2 Akademic Details Faculty/University ( name and address) Date of Graduation: 1990 Medical School / Firat University Postgraduate Training: ( Name and address of Center and Supervisor [s] in charge of Training) 1-Training of Internal Medicine Firat University Medical School Department of Internal Medicine ELAZIG 2-Training of Medical Oncology Hacettepe University Institute of Oncology Ankara, Turkey SUPERVISOR IN CHARGE OF TRAINING: From To 1-Training of Internal Medicine : Training of Medical Oncology: Title of thesis: 1. Effectiveness of Intravenous Omeprazole and Ranitidine For Gastrointestinal Bleedings of Acid-Peptic Disease 2. The prognostic significance of cyclin D1, p27, and cyclin E and their correlations wih other prognostic factors in stage III epithelial ovarian carcinoma Accreditation: Government body (Name, number and date of certificate issued by Universty, Medical Association or Government Body) Academic Experience: Associate Professor Memberships: 1-European Society for Medical Oncology 2-Anatolian Society for Medical Oncology (Turkey) 3-Society for Oncology Group (Turkey)
3 4-Society for Medical Oncology (Turkey) 5-Society for Internal Medicine (Turkey) 6-Society for Firat University Internal Medicine International Publications 1. Karaoglu A, Aydin S, Dagli AF, Cummings DE, Ozercan IH, Canatan H, Ozkan Y. Expression of obestatin and ghrelin in papillary thyroid carcinoma. Mol Cell Biochem Nov 28. [Epub ahead of print] 2. Dagli AF, Aydin S, Karaoglu A, Akpolat N, Ozercan IH, Ozercan MRGhrelin expression in normal kidney tissue and renal carcinomas. Pathol Res Pract Dec 1. [Epub ahead of print] 3. Topkan E, Polat Y, Karaoglu A. Primary mucinous adenocarcinoma of appendix treated with chemotherapy and radiotherapy: a case report. Tumori, 94, (2008). 4. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O, Unek T, Yilmaz U. Epidemiology and Survival of Hepatocellular Carcinoma in Turkey: Outcome of Multicenter Study. Jpn J Clin Oncol Aug Celik H, Gurates B, Karaoğlu A, Yavuz A, Dagli F, Ozercan R. Uterine primitive neuroectodermal tumor: a case report. Arch Gynecol Obstet Jun 4. [Epub ahead of print] 6. Topkan E, Karaoglu A. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease. J Exp Clin Cancer Res. 26(4):553-9 (2007.) 7. Topkan E, Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology. 2006;71(5-6): Aydin S, Geckil H, Karaoglu A, Elkiran ET. Med Hypotheses. 2007;69(5): Ghrelin: a novel peptide with therapeutic effect in certain cancers? 9. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer. 15;7:48 (2007) 10. Balci TA, Ciftci I, Karaoglu A. Incidental DTPA and DMSA uptake during renal scanning in unknown bone metastases. Ann Nucl Med. 20(5):365-9, (2006)
4 11. Elkıran E, Aygen B, Karaoğlu A, Altundag K. Metastatic Osteosarcoma to The Brain in Adult Patient. J Neurooncol. 76(2):213 (2006) Erma M, Baltalı E., Karaoğlu A, Abali H, Engin H, Ozisik Y, Guler N, Altundag K, Atahan IL, Sayek I, Tekuzman G. A Phase II Study on The Safety and Efficacy Of 5- Fluorouracil, Epirubicin, Cyclophoshpamide (FEC) Followed By Paclitaxel In The Adjuvant Treatment Of Breast Cancer. Cancer Invest 23 (3): (2005). 13. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212: (2005). 14. Nazıroğlu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E adminstration protects cisplatin-induced oxidative damage on renal, liver, and lens tissues in rats, Toxicology, 195, (2004). 15. Karaoğlu A, Yalcin S, Tekzuman G, Kars A, Çelik I, Güler N, Özışık Y, Türker A, Barışta Đ, Güllü Đ. Weekly irinotecan in patients with metastatic colorectal cancer failing 5- Fluorouracil-based chemotherapy : Efficacy and Prognostic Factors. Tumori, 89, (2003). 16. Karaoğlu A, Altundağ K, Erman M, Engin H, Güllü Đ. Familial asynchronous bilateral primary male breast carcinoma. J Exp. Clin Cancer Res, 21, (2002). 17. Erman M, Karaoğlu A, Öksüzoglu B, Aydingöz U, Ayhan A, Güler N. Solitary esophageal metastases of breast cancer after 11 years : a case report. Med Oncol, 19, (2002). 18. Engin H, Abalı H, Erman M, Karaoğlu A, Çelik Đ, Güler N. Central nervous system sleeding as a first manifestation of immun thrombocytopenic purpura in hodgkin disease. Haematologia (Budap), 31, (2002).
5 Presentations at International Scientific Meetings: 1. Balcı TA, Ciftci I, Karaoglu A. An Unusual Tumor Of The Renal Pelvis : Primary Mucinous Adenocarcinoma. A Case Report. XXIII. World Congress Of Pathology And Laboratory Medicine. May 26 th -30 th 2005 Istanbul-Turkey. 2- Elkiran T, Celebi S, Aygen B, Karaoglu A, Ozercan I. Primary Malignant Melanoma Of Esophagogastric Junction : A Case Report. XXIII. World Congress Of Pathology And Laboratory Medicine. May 26 th -30 th 2005 Istanbul-Turkey. 3-Aygen B, Elkiran T, Karaoglu A, Akpolat A. An Unusual Tumor Of The Renal Pelvis : Primary Mucinous Adenocarcinoma. A Case Report. XXIII. World Congress Of Pathology And Laboratory Medicine. May 26 th -30 th 2005 Istanbul-Turkey 3- Karaoğlu A, Güler N, Doğan I, Ayhan A, Erman M, Öksüzoğlu B, Çelik Đ, Karaağaoğlu E, Ayhan A. The prognostic significance of cyclin D1, p27, and cyclin E and their correlations wih other prognostic factors in stage III epithelial ovarian carcinoma. 27 th ESMO Congress, October, Nice, Annal Oncol, Vol 13, 111, Karaoğlu A, Yalcin S, Tekuzman G, Erman M, Altundağ O, Oksuzoglu B, Engin H, Altundag K, Guler N. A phase II Study of weekly irinotecan in patients with metastatic colorectal cancer refractory to 5- FU based chemotherapy, American Society of Clinical Oncology, Thirty-Seventh Annual Meeting., May 12-15, Öksüzoglu B, Güler N, Engin H, Karaoğlu A, Baltalı E, Tekzuman G. Intraductal Carcinoma Patients. The Breast Journal, Vol 7, , 2001, 6-. Karaoğlu A, Yalcin S, Tekuzman G, Erman M, Altundağ O, Oksuzoglu B, Engin H, Altundag K, Guler N. A phase II Study of weekly irinotecan in patients with metastatic colorectal cancer refractory to 5- FU based chemotherapy. American Society of Clinical Oncology, Thirty-Seventh Annual Meeting., May 12-15, Öksüzoğlu B, Güler N, Engin H, Baltalı E, Karaoğlu A, Altundağ K, Altundağ Ö, Erman E, Özısık Y, Altundağ K. Salvage ifosfamide-etoposide combination after antracycline and taxane failure in advanced breast cancer patents. 11. International Congress on Anti-Cancer Treatment, February 6th to 9th, Paris-France, Karaoğlu A, Baltali E, Engin H, Erman M, Öksüzoğlu B, Altundağ Ö, Altundağ K, Özısık Y, Güler N, Tekzuman G. Combination of docetaxel, epirubicin, cyclophosphamide chemotherapy in metastatic breast cancer. 11. International Congress on Anti-Cancer Treatment, February 6th to 9th, Paris-France, Engin H, Üner A, Öksüzoğlu B, Karaoğlu A, Altundağ K, Tekzuman G. Lymphoblastic leukemia/lymphoma in adults. A clinicopathological study of 28 cases treated at the Hacettepe University Oncology Institute. 11. International Congress on Anti-Cancer Treatment. February 6th to 9th, Paris-France, 2001
6 10. Erman M, Baltali E, Engin H, Karaoğlu A, Özısık Y, Güler N, Altundağ K, Atahan L, Sayek Đ, Tekzuman G. FEC followed by paclitaxel in the adjuvant treatment of high-risk breast cancer: preliminary report. Adjuvant Therapy of Primary Breast cancer, 7th International Conference February St Gallen/Switzerland, Abali H, Karaoğlu A, Tekzuman G, Koc Y, Kansu E. IIVP regimen for salvage therapy in patients with relapsed lymphoma prior to autologous stem cell transplantation. American Society of Hematology, Forty-third Annual Meeting, December, Orlanda-Florida, Baydas G, Dönder E, Erçel E, Karaoğlu A, Yılmaz O, Çelik S. Effects of daily vitamin E supplementation on oxidative status and fatty acid composition in rats with diabetes mellitus induced with streptozotocin. 19 th Conference Of European Comparative Endocrinologists, Nijmegen, 1998.
CURRICULUM VITAE. Key Qualifications: Internal Medicine Specialist and Medical oncologist. Name of Hospital: Firat Universitesi Hastanesi
CURRICULUM VITAE Personal Details Surname: Elkiran First Name: Emin Tamer Akademic title/ position: Associate professor of Medicine Key Qualifications: Internal Medicine Specialist and Medical oncologist
More information4-Deveci F, Akbulut HH, Çelik I, Muz MH Ilhan F. Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients, Mediators Inflamm., 2006;(2);89070.
CURRICULUM VITAE Personal Details Surname: Muz Frst Name: Mehmet Hamdi Academic title/position: Prof. Dr.- President of Chest Disease Departmant Key Qualifcations: Research Interest: Lung Cancers Đnternational
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationCURRICULUM VITAE. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system
CURRICULUM VITAE Personal Details Surname: BAHCECIOGLU First Name: Ibrahim Halil Akademic title/ position: Prof. Dr. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system Research Interest:
More informationLocoregional & advanced esophagus or esophagogastric junction cancer
Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More information2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-
Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationNews Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationProton Therapy Center Czech
Proton Therapy Center Czech The main goal of radiotherapy is to irreversibly damage tumor cells, whereas the cells of healthy tissue are damaged only reversibly or not at all. Proton therapy currently
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationOur Facility. Advanced clinical center with the newest and highly exact technology for treatment of patients with cancer pencil beam
PTC Czech The main goal of radiotherapy is to irreversibly damage tumor cells, whereas the cells of healthy tissue are damaged only reversibly or not at all. Proton therapy currently comes closest to this
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationMEDICAL POLICY POLICY TITLE
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): Effective Date: April 15, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the administration
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationYour Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationReceptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationA23: Oncologic Disease- Tumor Markers
A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More information10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationPediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
More informationFalse positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationMICRONUTRIENTS IN CANCER
MICRONUTRIENTS IN CANCER Dr. Bilwa Bhanap, MD Scope of the problem 2000 1500 Heart Disease 12 million people worldwide are diagnosed with cancer every year. This is expected to rise to 27 million by 2030.
More informationSequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study
JBUON 2013; 18(2): 314-320 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective
More informationSUPERVĐSOR ĐN CHARGE OF TRAINING: Şef Dr Kunter Perim
CURRICULUM VITAE Personal Details Surname: Deveci First Name: Figen Academic title/position: Prof, Departmant of Chest Disease Key Qualifcations: Research Interest: Asthma Bronchiale Đnternational Experience/Collaborations:
More informationRole of clinical trials in professional development
Role of clinical trials in professional development Peeter Padrik Tartu University Hospital University of Tartu Estonian Society for Medical Oncology How we do treatment decisions? Personal experience?
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationCase Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)
More informationNumber. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
More informationCancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery
Cancer treatment TOP EUROPEAN CANCER EXPERTISE The path to recovery 0% LAND OF HIGH QUALITY HEALTHCARE Located in Finland, a land of high quality healthcare, Helsinki University Hospital is regarded as
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationSurvivorship Care Plans Guides for Living After Cancer Treatment
Survivorship Care Plans Guides for Living After Cancer Treatment Institute of Medicine Report 2005 Recommendations for meeting needs of cancer survivors Implement survivorship care plan Build bridges
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationNew Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
More informationPATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.
PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. Radiation Oncology Sidney Kimmel Cancer Center at Johns Hopkins Last
More informationWhat is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationCurrent Status and Future Direction of Proton Beam Therapy
Current Status and Future Direction of Proton Beam Therapy National Cancer Center Hospital East Division of Radiation Oncology and Particle Therapy Tetsuo Akimoto Comparison of status of particle therapy
More informationmicrorna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS
microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS 1st International Congress on Controversies in Personalized Oncology (CONPO) BARCELONA, SPAIN MARCH
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationCo-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
More informationOutcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy
ORIGINAL ARTICLES 613 Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy S K Tay,*FAMS, MD, FRCOG, L K Tan,**MBBS, M Med (O & G), MRCOG Abstract
More informationtrastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd
trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationTrastuzumab (Herceptin ) for patients with metastatic breast cancer
JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationCharacterisation of a Palliative Care Population in a Comprehensive Cancer Centre
Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre Kirstine Skov Benthien, Mie Nordly, Katja Videbæk, Lisbeth Grave Bendixen, Louise Christoffersen, Hans von der Maase, Geana
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Norm D. Smith, M.D. Chief of Urologic Oncology Department of Urology Northwestern University Feinberg School of Medicine The Problem Bladder cancer Superficial disease
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationNational Cancer Drugs Fund List (Updated 13 February 2014)
National Cancer Drugs Fund List (Updated 13 February 2014) DRUG Abiraterone Aflibercept Axitinib Bendamustine NCDF APPROVED CRITERIA The treatment of metastatic castration resistant prostate cancer where
More informationE UROPEAN CURRICULUM VITAE FORMAT
E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Address VALENTINA GUARNERI University of Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Istituto Oncologico Veneto
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationMetastatic Breast Cancer: RAOM Clinical Practice Guidelines
Russian Association of Oncological Mammology http://www.breastcancersociety.ru/ http://breastcancergroup.net / http://www.bcguidelines.ru/ Clinical recommendations of the Russian Brest Cancer Society for
More informationComparing Immunotherapy with High Dose IL-2 and Ipilimumab
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationOvarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health
Ovarian Cancer in Georgia, 1999-23 Georgia Department of Human Resources Division of Public Health Acknowledgments Georgia Department of Human Resources......B. J. Walker, Commissioner Division of Public
More informationOncology. Topic-Bile Duct Carcinoma. Topic-Adenocarcinoma, Lung. Topic-Hemangiosarcoma, Spleen and Liver
Topic-Adenocarcinoma, Lung Figure 1. Pulmonary adenocarcinoma. Figure 2. Pulmonary bronchiolar carcinoma. Figure 3. Pulmonary fibrosarcoma. Topic-Adenocarcinoma, Skin (Sweat Gland, Sebaceous) Figure 1.
More informationGastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Cetuximab INDICATION: chemotherapy Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationSmall-Cell Lung Cancer: Is There a Standard Therapy?
Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone
More informationBOLETIN BIBLIOGRAFICO BIBLIOTECA MEDICA-HCG JUNIO 2014
BOLETIN BIBLIOGRAFICO BIBLIOTECA MEDICA-HCG JUNIO 2014 Am J Clin Pathol 1. 2013 Statement on Human Papillomavirus DNA Test Utilization. AJCP 141 (4): 459-461, abr. 2014 2. Pathology Consultation on Electronic
More informationIntraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationHospital-Based Tumor Registry. Srinagarind Hospital, Khon Kaen University
Hospital-Based Tumor Registry Srinagarind Hospital, Khon Kaen University Statistical Report 2012 Cancer Unit, Faculty of Medicine Khon Kaen University Khon Kaen, Thailand Tel & Fax:+66(43)-202485 E-mail:
More informationBreast Cancer. Breast Cancer Page 1
Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationInspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015
Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating
More informationYttrium-90 Radioembolization
Yttrium-90 Radioembolization Yttrium-90 radioembolization is generally used as a palliative therapy for selected patients with unresectable tumors of the liver including: Metastatic tumors from colorectal
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationPathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
More informationCrosswalk for Positron Emission Tomography (PET) Imaging Codes G0230 G0030, G0032, G0034, G0036, G0038, G0040, G0042, G0044, G0046
Positron Emission Tomography (PET) CPT to HCPCS Level Crosswalk Changes below from CMS Change Request 3741 Transmittals 518 & 31 published on April 1, 2005; mplementation of CPT codes are effective January
More information